BioNTech maps pivotal oncology milestones for 2026
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
Artificial intelligence coupled with laboratory automation will transform how scientific work is performed
Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
Subscribe To Our Newsletter & Stay Updated